Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,364 public trials 2,842 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, Not Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • University of Miami Health System Miami, Florida, United States
  • AdventHealth Cancer Institute Orlando, Florida, United States
View all 136 locations
View Trial Details
Active, Not Recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Active, Not Recruiting

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT04217356

Conditions
Bone Marrow Cancer, Bone Marrow Diseases, Bone Marrow Neoplasms, +9 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • St. Paul's Hospital Vancouver, British Columbia, Canada
  • Nova Scotia Health Authority Halifax, Nova Scotia, Canada
View Trial Details
Active, Not Recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute Louisville, Kentucky, United States
  • John Theurer Cancer Center Hackensack, New Jersey, United States
  • Novant Health Charlotte, North Carolina, United States
  • Institut - Jules Bordet Anderlecht, Belgium
View all 88 locations
View Trial Details
Active, Not Recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

NCT03588299

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Arkansas Children's Hospital - Hematology / Oncology Little Rock, Arkansas, United States
  • C.S. Mott Children's Hospital - Hematology / Oncology Ann Arbor, Michigan, United States
  • UW Health Carbone Cancer Center Madison, Wisconsin, United States
  • SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD Sofia, Sofia City Province, Bulgaria
View all 13 locations
View Trial Details
Active, Not Recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University Of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope - Lennar Foundation Cancer Center Irvine, California, United States
  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center Denver, Colorado, United States
  • Karmanos Cancer Institute. Detroit, Michigan, United States
View all 24 locations
View Trial Details

Related conditions